Track: Bioanalytics - Chemical - Drug Quantification - Mass Spectrometry (LC-MS) Methods
Category: Late Breaking Poster Abstract
Simultaneous Analysis of COVID-19 Drugs Candidates in Human Plasma by LC-MS/MS
Purpose: Over 500 drugs are being tested for the treatment of COVID-19 all over the world . The lack of knowledge about proper concentration and pharmacokinetics could be an issue to propose the right dose. Here we present an optimized method for a simultaneous analysis and the quantification of nine COVID-19 drug candidates which is used in about 25 % of the clinical trials performed worldwide on COVID-19 patients: Favipiravir, Remdesivir, GS-441524, Chloroquine, Hydroxy-chloroquine, Desethylchloroquine, Azithromcyin, Ritonavir, and Lopinavir in human plasma using LC-MS/MS. Methods: The quantification of nine COVID-19 drug candidates was performed by LC-MS/MS method with ESI positive, in 4.5 min. The standard samples were prepared at the plasma concentrations; 50 ng/mL to 2000 ng/mL for Remdesivir, Favipiravir, Ritonavir, and Lopinavir, 2 ng/mL to 1000 ng/mL for Chloroquine, Hydroxychroloquine, Desethylchloroquine, and Azithromycin, and 10 ng/mL to 1000 ng/mL for GS441524. Stable isotope labelled standards corresponding to each COVID-19 drug candidate were used as the internal standards. Results: The developed LC method allowed for good separation of each compound, except for Chloroquine and its metabolites due to similar structure (Figure 1). Linearity of calibration curve, accuracy, and precision at low, medium, and high concentrations for each molecule are presented in Table 2. Both accuracy and precision at the concentrations (low, medium, and high) were well within the allowed regulatory criteria of < 15% deviation. Conclusion: The LC-MS/MS method for quantification of COVID-19 drug candidates in human plasma was developed. For higher concentration (out of the calibration curve), the range can be modified by diluting or injecting less: good linearity is maintained (data not shown but available on demand).